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Abstract 18 
Translation of stem cell research to industrial and clinical settings mostly requires large 19 
quantities of cells, especially those involving large organs such as the liver. A scalable reactor 20 
system is desirable to ensure a reliable supply of sufficient quantities of differentiated cells. To 21 
increase the culture efficiency in bioreactor system, high surface to volume ratio needs to be 22 
achieved. We employed a microcarrier culture system for the expansion of undifferentiated 23 
human embryonic stem cells (hESCs) as well as for directed differentiation of these cells to 24 
hepatocyte-like cells. Cells in single cell suspension were attached to the bead surface in even 25 
distribution and were expanded to 1 x 106 cells/ml within 2 days of hESC culture with 26 
maintenance of the level of pluripotency markers. Directed differentiation into hepatocyte-like 27 
cells on microcarriers, both in static culture and stirred bioreactors, induced similar levels of 28 
hepatocyte-like cell differentiation as observed with cells cultured in conventional tissue culture 29 
plates. The cells expressed both immature and mature hepatocyte-lineage genes and proteins 30 
such as asialoglycoprotein receptor-1 (ASGPR-1) and albumin. Differentiated cells exhibited 31 
functional characteristics such as secretion of albumin and urea, and CYP3A4 activity could be 32 
detected. Microcarriers thus offer the potential for large-scale expansion and differentiation of 33 
hESCs induced hepatocyte-like cells in a more controllable bioreactor environment. 34 
  35 
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1. Introduction 36 
Among many organs and tissues for which cell therapies are being pursued, the liver is an organ 37 
that lacks effective therapies for liver failure. The liver is the largest organ in the adult body and 38 
has major functions in metabolism and detoxification, playing a role in protein synthesis, glucose 39 
metabolism and lipid metabolism. Existing treatments for liver failure are limited, and the only 40 
real cure is liver cell or organ transplantation. The shortage of donor cells and organs often 41 
makes it unreachable for a large number of patients. Hepatocytes isolated from liver and cultured 42 
in vitro have limited proliferation potential and often very quickly lose their functional attributes. 43 
Therefore, investigators are looking into the possibility to generate hepatocytes from progenitor 44 
cells or stem cells. However, any therapeutic application requires a large quantity of cells in the 45 
order of >109-1010 cells per treatment.  In addition to the clinical need for hepatic cell 46 
transplantation, human hepatocytes attract attention from the pharmaceutical industry for drug 47 
toxicity and metabolism testing to better estimate acute and chronic toxicity, which should 48 
decrease the failure of drugs in clinical trials. The shortage of human livers also makes it difficult 49 
to use primary human hepatocytes for pharmaceutical purposes. 50 
The cultivation of hepatic progenitor cells, immortalization of hepatocytes, and derivation of 51 
functional hepatocytes from stem cells are among the more prevalent approaches (Agarwal et al., 52 
2008; Allain et al., 2002; Cai et al., 2000; Hay et al., 2008; Herrera et al., 2006; Wege et al., 53 
2003). Especially, the progress in stem cell science has opened the possibility that many types of 54 
stem cells including embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), 55 
pluripotent adult stem cells, hematopoietic stem cells (HSCs) and mesenchymal stem cells 56 
(MSCs) can be used to produce hepatocyte-like cells (Zhang et al., 2012).  Hepatic cells derived 57 
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from pluripotent stem cells (PSCs), which are capable of unlimited self-renewal have great 58 
potential to be such a steady cell source.  59 
For stem cells to be widely applied to clinical and pharmaceutical fields, having a desired cell 60 
type as well as a sufficient supply of those cells should be fulfilled. The conventional method of 61 
expanding and differentiating PSCs in tissue culture plates is labor intensive and difficult to scale 62 
up. Employing a scalable reactor system can enable ample supply of differentiation competent or 63 
differentiated cells to meet such a clinical need. Various reactor systems have been investigated 64 
to support stem cell expansion and differentiation towards hepatocytes; rotary culture systems, 65 
perfusion culture systems, and stirred suspension systems have been employed for hepatic cell 66 
cultures (Matsumoto et al., 2008; Miki et al., 2011; Wang et al., 2012; Yin et al., 2007). Among 67 
those systems, stirred suspension culture has the advantage of having been widely used in 68 
growing mammalian cells for decades. It also allows high-density culture in a more 69 
homogeneous environment, and should allow one to monitor and control culture parameters. 70 
Cells are suspended in culture either as spheroids or with the support of scaffold. Stirred reactor 71 
cultures have been used to expand or differentiate hematopoietic stem and progenitor cells 72 
(HSPCs), neural stem cells (NSCs), and human and mouse embryonic stem cell (ESCs) grown as 73 
embryoid bodies (EBs) (Cameron et al., 2006; Fok and Zanstra, 2005; Gilbertson et al., 2006; Li 74 
et al., 2006).  75 
Microcarriers have also been used as scaffold to support differentiation in stirred suspension 76 
culture. Microcarriers are particles, typically made of cellulose, glass, plastic, or polyester, and 77 
usually with diameters of 100-250 μm. Microcarriers have the advantage of providing a large 78 
surface area for a given reactor volume. By providing surface for attachment, they allow 79 
anchorage dependent cells to be cultivated in stirred bioreactors for a large-scale. 80 
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Undifferentiated PSCs were seeded onto the beads, expanded further, and differentiated into 81 
different cell types, including neural progenitor cells and cardiomyocytes (Bardy et al., 2013; 82 
Lecina et al., 2010; Rodrigues et al., 2011). Few studies have assessed hepatic differentiation on 83 
microcarriers. Rat multipotent adult progenitor cells (rMAPCs) have been expanded and 84 
differentiated on dextran beads in a spinner system to yield hepatocyte-like cells expressing early 85 
and mature hepatic genes (Park et al., 2010). hESCs have also been expanded on different types 86 
of beads and differentiated into endodermal cells (Lock and Tzanakakis, 2009), showing the 87 
potential of scaled-up culture of ESC hepatic differentiation using microcarrier-based suspension 88 
culture. Although most micro-porous microcarrier cultures are still 2D, the stirred bioreactor 89 
allows more dynamic culture environment than in conventional 2D culture in tissue culture 90 
plates. In this study, using an established hepatic differentiation protocol (Roelandt et al., 2012; 91 
Roelandt et al., 2010), we show that hESCs can be differentiated into hepatocyte-like cells on 92 
dextran microcarriers in suspension culture system. Microcarrier culture has the potential of 93 
being an efficient scalable means of undifferentiated hESC expansion for a short period and 94 
directed differentiation towards hepatocytes. 95 
 96 
  97 
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2. Materials and methods 98 
2.1. hESC culture  99 
The human H9 cell line was used in this study, with approval of the ethics committee at KU 100 
Leuven. H9 cells were cultured in a feeder free condition on hESC qualified Matrigel™ (BD) 101 
coated surface and with mTeSR1™ (Stem cell technologies) medium.  102 
2.2. hESC cell seeding onto microcarriers for suspension culture 103 
Cytodex, a crosslinked dextran microbead, is microporous, with a void fraction greatly 104 
exceeding 90%, and supports cell growth on the external surface of the bead. Cytodex 1 and 105 
Cytodex 3 microcarriers were purchased from GE Healthcare as dry powder. Collagen based 106 
microcarriers, Cultispher and Spherecol, were tested for cell seeding and differentiation. 107 
Cultispher S (Sigma) are macroporous gelatin microcarriers. Spherecol® (Advanced BioMatrix) 108 
are purified collagen beads. The microcarrier stock was prepared by washing 1 g of microcarrier 109 
powder with PBS for 3-5 times. Swollen beads were sedimented in 100 ml fresh PBS and 110 
sterilized by autoclaving.  111 
Prior to seeding the hESC, microcarriers were washed with DMEM/F12 (Life technologies) 112 
twice. Matrigel with reduced growth factors (BD) was diluted in DMEM/F12 in 1: 5 and added 113 
to the washed beads to make a final dilution 1:10. Beads were stirred in the Matrigel solution for 114 
2 hours at 37°C. hESC cultures in 6 well plates (Corning) were washed with PBS. 1 ml Accutase 115 
(Sigma) was added to each well, and the plates were incubated at 37°C for 5 min. The plates 116 
were lightly tapped several times and gently pipetted to make single cell suspension. 2 ml of 117 
DMEM/F12 was added to each well to neutralize accutase. The cells were collected, centrifuged, 118 
and resuspended in mTeSR1 medium at a concentration of 5x106 cells/ml. Cells were added to 119 
7 
 
25 mg/ml Cytodex microcarriers at the concentration of 5 x 106 cells/ml in 5 ml culture medium. 120 
The mixture was incubated for 2 hrs at 37°C to allow initial cell attachment to the beads with 121 
occasional shaking of the tube. Then the mixture was transferred into either a low attachment 122 
plates (Corning) or a spinner flask (Bellco). The culture was stirred at 20-25 rpm on a magnetic 123 
stir plate (2mag) and maintained at 37°C, 21% O2 tension and 5% CO2 for 2-3 days of expansion 124 
with medium change every day. 90% of medium was removed carefully when cell-laden beads 125 
were sedimented, and then 100% of fresh medium was added to the flask. 126 
2.3. In vitro Hepatic differentiation 127 
hESC were differentiated into hepatocyte-like cells using a four step hepatic differentiation 128 
protocol developed in Verfaillie lab (Roelandt et al., 2012). For static plate differentiation, cell 129 
laden beads were inoculated in an ultra-low attachment 6-well plate (Corning) at a starting cell 130 
concentration of 1.0 x 106 cells/ml.  After 2 days of expansion culture, the cells reached 131 
confluency on the microcarrier surface, they were washed once with PBS and resuspended in 132 
hepatic differentiation medium (2 ml of differentiation medium per well for static differentiation 133 
and 50 ml in a 250ml spinner flask for stirred suspension differentiation). The composition of 134 
serum free differentiation basal medium is a 60/40 (v/v) mixture of low glucose Dulbecco’s 135 
Modified Eagle media (DMEM) (Life technologies) and MCDB-201 (Sigma) supplemented with 136 
0.026 µg/ml ascorbic acid 3-phosphate (Sigma), linoleic acid bovine serum albumin (LA-BSA, 137 
Sigma) (final concentrations of 0.25x103 µg/ml BSA and 2.03 µg/ml linoleic acid), insulin-138 
transferrin-selenium (ITS, Sigma) (final concentration 2.5 µg/ml insulin, 1.38 µg/ml transferring, 139 
0.0012 µg/ml sodium selenite), 0.4 µg/ml dexamethasone (Sigma), 4.3 µg/ml β-mercaptoethanol 140 
(Sigma). The growth factor supplements were added with the 90% medium change as follows: 141 
(i) day 0: Activin A (100 ng/ml) and Wnt3a (50 ng/ml); (ii) day 2: Activin A (100 ng/ml); (iii) 142 
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day 4: BMP4 (50 ng/ml); (iv) day 8: aFGF (50 ng/ml); (v) day 12: HGF (20 ng/ml). 143 
Differentiations were carried out at 21% O2 and 5% CO2, 37°C for 18 days with 60% media 144 
change every 2 days corresponding to the differentiation stage.  145 
2.4. RNA isolation and quantitative real time polymerase chain reaction (RT-qPCR) 146 
Total RNA was isolated from cell lysates using the RNAeasy minikit (Sigma) according to 147 
instructions provided in the kit. cDNA was synthesized from the extracted RNA using the Super-148 
script III reverse transcriptase (Life technologies) method. The PCR mix consisted of cDNA 149 
samples, SYBR Green Mix PCR reaction buffer (Life technologies) and primers (5 µM stocks, 150 
sequences in Table 1). The RT-qPCR reaction was run on a Realplex mastercycler (Eppendorf) 151 
using the following program: 50°C for 2 min, 95°C for 10 min, and 40 cycles at 95 °C for 15 s 152 
and 60 °C for 1 min followed by a dissociation protocol to obtain a melting curve. Transcription 153 
abundance relative to GAPDH was calculated as Δ Ct which is Ct (transcript of interest) – Ct 154 
(GAPDH) and transcript abundance in sample relative to control differentiation was calculated as 155 
Δ Ct (control) - Δ Ct (day of sample). 156 
2.5. Cell viability staining 157 
The live/dead viability/cytotoxicity kit (Life Technologies) was used to stain cells on 158 
microcarriers with calcein and ethidium. Component B was added first to DPBS (1:1000) and 159 
then component A was added to the solution (1:1000). Cells were incubated with the staining 160 
solution for 15-30 min at 37°C. Cells were washed once with PBS and observed under inverted 161 
fluorescent microscope (Axiovert, Zeiss). Live and dead cells appear as green and red 162 
respectively. 163 
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2.6. Albumin and ASGPR-1immunostaining 164 
Cell-laden microcarriers were fixed with 10% NBF for 15 min and washed with PBS 5 min each 165 
3 times. Fixed samples were treated with PBS with 0.2% Triton X-100 (PBST) for 10 min and 166 
blocked in 5% Goat serum in PBST for 1 h. Cell-laden-beads were stained with either an anti-167 
asialoglycoprotein receptor-1 (ASGPR-1) antibody (Thermoscientific, 1:10) or anti albumin 168 
antibody (Dako, 1:4000) in DAKO antibody diluent at 4°C for overnight and stained with 169 
Alexa488 anti-rabbit IgG or anti-mouse IgG (Life Technologies, 1:500) for 30 min. Cells were 170 
counter stained for nuclei with Hoechst (1:2000). Then cells-microcarriers were washed, 171 
resuspended in PBS, and observed under inverted fluorescent microscope (Axiovert, Zeiss).  172 
For flow cytometric analysis, cells were harvested from the microcarriers by trypsinization. After 173 
fixing with 4% PFA for 20 min and blocking for 1h in PBS with 3% (v/v) FBS, cells were 174 
incubated with anti ASGPR-1 antibody (1:10) for 30 min, followed by Alexa 488-conjugated 175 
goat anti-mouse IgG secondary antibody (1:500) for 30 min. Then cells were washed and 176 
resuspended in 500μl PBS for flow cytometry analysis using a FACS Canto (Becton Dickinson). 177 
2.7. Albumin and urea secretion assay 178 
The albumin secretion rate was quantified using the human albumin ELISA quantitation kit 179 
(Bethyl) according to instructions provided in the kit. Urea production rate was measured by 180 
using QuantiChrom urea assay kit (BioAssay Systems) following the instructions provided in the 181 
kit for low urea samples. 182 
2.8. CYP3A4 activity assay 183 
CYP3A4 activity was quantified using either P450-Glo™ CYP3A4 assay with Luciferin-IPA kit 184 
(more selective substrate for CYP3A4) or Luciferin-PFBE (commonly used in the published 185 
10 
 
literature, but which measures general CYP3A activity aside from CYP3A4) (Promega) 186 
according to instructions provided in the kit.  187 
2.9. Cell enumeration by nuclei counting 188 
Microcarriers from 1 ml culture were centrifuged at 1000 rpm for 30s to remove supernatant. 189 
Cells-microcarriers were washed once with PBS and treated with Liberase™ for 30-60 min. 190 
Cells were detached from the microcarriers by gentle pipetting to make single cell suspension. 191 
Cells were separated from the beads using a 100 µm filter and diluted for cell counting using 192 
Nucleocounter (Chemometec). 193 
For fixative staining, cells on microcarriers in 1 ml were stained by adding a drop or two fixative 194 
staining solution (0.5% (w/v) crystal violet in 40% ethanol and 60% PBS) for 1-2 min. Stained 195 
cell-microcarriers were washed with PBS twice to remove the staining solution from the 196 
supernatant.  197 
2.10. Statistical analysis 198 
Experiments were repeated at least 3 times for each condition. Data from representative 199 
experiments are presented; whereas similar trends were seen in other multiple trials. All error 200 
bars represent standard deviation.  201 
  202 
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3. Results 203 
3.1. hESC expansion and maintenance of pluripotency on microcarriers 204 
hESCs are often cultured on mouse embryonic feeders, and passaged as small colonies for 205 
expansion. This makes it difficult to control the exact number of cells and the distribution of 206 
cells in tissue culture plates, and even more so for microcarrier cultures. To solve this problem, 207 
we isolated hESCs, cultured in mTeSR1 on hESC expansion Matrigel, as single cell suspension 208 
prior to seeding in plates or on microbeads for differentiation. hESCs, seeded as single cells and 209 
with a defined concentration (1.3 x 105 cell/cm2), were allowed to attach to growth factor 210 
reduced differentiation Matrigel coated microcarriers or culture plates in mTeSR1 medium for 2 211 
days before we started differentiation. In conventional differentiation using tissue culture plates, 212 
following standard differentiation, gene expression profile of hepatic markers and functional 213 
assay, in particular CYP3A4 activity was comparable between differentiations starting with 214 
single cell suspensions or with colonies (Fig. 1).  215 
Different types of microcarriers with various materials including dextran beads with either 216 
positive charge or collagen layer (Cytodex 1 and Cytodex 3), collagen beads (Spherecol), and 217 
gelatin beads (Cultispher) were screened to select microcarriers for hESC hepatic differentiation. 218 
The expression levels of hepatic markers were higher in cells differentiated on dextran beads. 219 
Attached cells were clearly visible on the transparent dextran beads. Based on the hepatic gene 220 
expression level and the ease of cell-bead handling, Cytodex 3 was chosen for further analysis 221 
for hESC differentiation to hepatic cells (Fig. 2).   222 
hESCs, isolated as a single cell suspension, were inoculated onto microcarriers at a seeding 223 
densities of 1.25 x 105, 2.5 x 105, 4.0 x 105, and 8.0 x 105 cells/mg bead and cultured for 3 days 224 
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to determine the optimal seeding density to reach confluent cell density after 2 days of expansion 225 
culture. With a seeding density of 8.0 x 105 cells/mg bead, cell density reached confluence after 226 
2 days of expansion while lower seeding densities did not reach confluence after 3 days 227 
(Supplementary Table 1 and Fig. 3).  228 
The total number of cells was inoculated onto beads at high concentration in 2-3 ml culture 229 
medium and incubated at 37°C for 2 hours with intermittent shaking every 5 minutes in order to 230 
increase the frequency of direct contact between microcarriers and cells. At this initial seeding 231 
density, many cells attached to beads in even distribution within 2 hours.  The attachment 232 
efficiency was about 25%. The cell-laden microcarriers were then transferred into either low 233 
attachment 6-well plates or a 100 ml spinner flask with a 50 ml working volume of mTeSR1 234 
medium at a final density of 8 x 105 cells/mg bead. After the initial 2 days in culture, viable 235 
hESCs covered the majority of the bead surface, and no empty beads could be detected (Fig. 3A 236 
and 3B).  237 
When the cell concentration increased to 1.0 x 106 cells/ml, a plateau was reached (Fig. 3C) and 238 
the cell concentration or cell density on the beads did not increase any further, due to surface 239 
area restriction. By adjusting the initial seeding density to 8 x 105 cells/mg bead, we could 240 
control the time required to ensure that cells on the microcarrier surface became confluent, i.e. 241 
after two days following the seeding. The population doubling time on the microbeads was about 242 
31h between day 0 and day 2, similar to that of H9 cell doubling in culture plates. As the cells 243 
became confluent on the beads, cell-laden beads started to agglomerate, but cells did not form 244 
multi-layers on the surface of the beads.  245 
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The expression levels of key hESC transcripts, octamer-binding transcription factor (OCT4), 246 
SRY (sex determining region Y)-box 2 (SOX2), and NANOG were assessed by RT-qPCR at day 247 
0 (which also can represent the gene expression level of cells cultured in tissue culture plates) 248 
and day 2. Pluripotency gene expression was sustained at high levels during hESC proliferation 249 
(Fig. 3D). This demonstrates that the seeding method used prior to the expansion of hESC on 250 
microcarriers allows hESCs to become evenly distributed and achieve cell-confluency on 251 
microcarriers with maintained pluripotency during 2 day expansion culture. 252 
3.2. Hepatocyte differentiation of hESC on microcarriers 253 3.2.1. Differentiation in static culture 254 
The feasibility of employing microcarriers for hESC differentiation to hepatocyte-like cells was 255 
first investigated in static culture. Cells were expanded on microcarriers for 2 days to generate a 256 
confluent monolayer of cells. mTeSR1 medium was then replaced with differentiation medium 257 
containing growth factors as described in the materials and method section. Cell density 258 
decreased during step 1, slightly increased until day 12 (by morphological observation, data not 259 
shown), and then an overall decrease was seen to a final concentration of 3.8 x 105 cells/ml on 260 
day 18, which is similar to the cell number recovered from cells allowed to differentiate in tissue 261 
culture plates (Fig. 4A). As the differentiation proceeded, cell morphology changes were similar 262 
to those seen in hepatic differentiation in 2D on tissue culture plates, and the cells remained 263 
highly viable (Fig. 4B). As cells proliferated on microcarriers, cell-microcarriers form bigger 264 
bead-bead agglomerates allowing cells to grow in between the beads.  265 
The level of hepatocyte-specific transcripts was evaluated at the end of the differentiation in 266 
microcarrier culture, and compared with cells cultured in culture dishes. Hepatocyte related 267 
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transcripts of alpha-feto-protein (AFP), albumin (ALB), glucose-6-phosphatase (G6P), 268 
microsomal glutathione S-transferase 1 (MGST1), FACTOR V, hepatocyte nuclear factor 269 
(HNF4α), cytochrome P450 family 3 subfamily A polypeptide 4 (CYP3A4), sodium/bile acid 270 
cotranspoter Na/Taurocholate cotransporting polypeptide (NTCP), orosomucoid 1 (ORM1), 271 
multidrug resistance-associated protein 2 (MRP2), glutathione S-transferase alpha (GSTα), 272 
phosphoenolpyruvate carboxykinase 1 (PEPCK1) were expressed at the end of differentiation 273 
(day 18) (Fig. 4C and 4D), with the averaged expression level of the hepatocyte marker 274 
transcripts from three replicate experiments comparable to that seen in differentiations carried on 275 
culture plates. Immunostaining for ALBUMIN, asialoglycoprotein receptor-1 (ASGPR-1), 276 
CYP3A4/5/7, and PEPCK identified regions of positive cells on the microcarriers (Fig. 5A). By 277 
flow cytometry, about 20% of the cells expressed ASGPR-1 (Fig. 5B), which is a type II 278 
transmembrane glycoprotein expressed on mature hepatocytes. As expected from the hepatic 279 
differentiation in tissue culture plates in previous studies, about 20% of cells were directed to 280 
hepatocytes with mature markers. The rest of the differentiated cell population consists of mostly 281 
immature hepatocytes and immature cells of other lineages (ex. Mesodermal cells expressing 282 
FLK1). We addressed how many cells also had endothelial and hepatic stellate cell features in 283 
the final differentiated population, but there was negligible expression of CD32b, CD31 and 284 
GFAP. 285 
Microcarriers have a high surface to volume ratio allowing cell culture with high cell 286 
concentration. We therefore tested if hepatic differentiation on microcarriers is feasible at higher 287 
cell concentration than conventional differentiation in tissue culture plates, which will be 288 
required in up-scaled culture system. Cell concentration at the beginning of differentiation was 289 
increased 2 times and 4 times respectively. Compared to differentiation in conventional tissue 290 
15 
 
culture plates, the cell yield from microcarrier cultures reached a 3 and 6 times higher final cell 291 
concentration (1.3 x 106 and 2.5 x 106 cells/ml), respectively, compared with tissue culture plate 292 
cultures at the end of differentiation (Supplementary Fig. 1A). Cells differentiated at higher 293 
concentration showed comparable levels of hepatic differentiation by gene expression and 294 
albumin secretion rate (Supplementary Fig. 1B and 1C). 295 
3.2.2. Differentiation in stirred suspension culture 296 
Next, hESC were expanded on microcarriers in a spinner flask and subsequently differentiated to 297 
the hepatocyte lineage in a spinner flask to confirm that the static microcarrier culture can be 298 
translated to a larger-scale bioreactor system. hESC were seeded on microbeads as described 299 
before. Upon reaching confluence, the hESC-laden microcarriers were washed with PBS once 300 
and resuspended in differentiation medium as per the differentiation protocol. With a stirring rate 301 
above 30 rpm, most cells detached from the microcarriers, and there was increased cell loss in 302 
general during the early phase of differentiation, which led to many void beads making it 303 
impossible to continue the culture (Supplementary Fig. 2). Using a stirring rate of 20-25 rpm, 304 
beads still agglomerated together, but at a lesser degree than in the static culture. The final 305 
concentration of cells at the end of differentiation was 5.9 x 105 cells/ml (Fig. 6A). The 306 
morphological changes of the cells on the beads cultured in the stirred bioreactor were similar to 307 
those seen in static culture. Throughout the differentiation on microcarriers in the stirred 308 
bioreactor, cells retained high viability (Fig. 6B). Transcripts for immature hepatocyte genes 309 
AFP and HNF4α were expressed at a high level. Transcripts for the more mature hepatic genes, 310 
ALB, NTCP, ORM1, G6P, MGST1, FACTOR V, MRP2, PEPCK1, GSTα, CYP3A4 increased 311 
significantly by day18 of the hepatocyte differentiation (Fig. 6C). The expression level of mature 312 
transcripts was comparable to that in static microcarrier differentiation or differentiation on 313 
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tissue culture plates. Regions of positive cells were stained for ALBUMIN and ASGPR-1 (Fig. 314 
6D).  315 
3.2.3. Functional characteristics of the differentiated cells 316 
In static microcarrier differentiation, the average albumin secretion rate was 2.26 µg/ml/106 cells, 317 
while urea was produced at 32.9 µg/ml/106 cells. In stirred microcarrier differentiation, albumin 318 
secretion rate was 1.77 µg/ml/106 cells, and urea genesis was 31.8 µg/ml/106 cells. CYP3A4 319 
activity was 532 RLU/ml/106 cells in static differentiation and 779 RLU/ml/106 cells. These 320 
functional parameters were similar and not statistically different from those found in 321 
conventional 2D differentiation in tissue culture plates (Table 2). Thus, hESC can be 322 
differentiation into hepatocyte-like cells on microcarriers cultured in stirred bioreactors, reflected 323 
by the up-regulation of hepatocyte gene transcripts and functional characteristics including 324 
albumin and urea production, and CYP3A4 activity.  325 
4. Discussion 326 
Pluripotent stem cells including ESCs and iPSCs have been used as a cell source in directed 327 
hepatic differentiation in the past years (Hannan et al., 2013; Roelandt et al., 2012; Roelandt et 328 
al., 2010; Sancho-Bru et al., 2009; Si-Tayeb et al., 2010; Song et al., 2009). This progress raises 329 
the expectation that such stem cell-derived hepatocytes could be applied for cell transplantation 330 
or in bioartificial liver devices. Hepatocyte-like cells induced from iPSCs, which are derived 331 
from patients with different genetic backgrounds, could also be used for toxicity and metabolic 332 
studies. For these advances in stem cell differentiation protocols to be suitable for clinical or 333 
pharmaceutical use, development of robust bioprocesses that are capable of producing large 334 
numbers of hepatic cells is required. The feasibility of cultivating PSCs and their progenies in 335 
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various types of bioreactors including perfusion reactors, rotating vessels, spinner reactors and 336 
others, has already been demonstrated (Bauwens et al., 2008; Cameron et al., 2006; Fok and 337 
Zandstra, 2005; Schroeder et al., 2005). An ideal bioreactor system should be able to provide a 338 
more homogeneous culture environment and to provide for a high concentration of cells and easy 339 
access for quality control. A stirred suspension reactor system has more advantage in terms of 340 
high concentration cell culture and easy access. In suspension culture system, ESC proliferation 341 
and differentiation has been achieved as embryoid bodies (EBs). Anchorage dependent cells, 342 
such as hepatocytes, need a scaffold to attach, such as microcarriers, which can then be 343 
suspended in the culture system. Such a configuration allows the growth of anchorage-dependant 344 
cells in high density in a large-scale bioprocess. 345 
Different types of microcarriers with various materials such as dextran and gelatin (Cytodex 1, 346 
Cytodex 3, Cultispher, Spherecol) are available for hepatic differentiation. Collagen derived 347 
beads may provide an advantage when the cells are harvested from the beads since the beads 348 
themselves can be degraded by enzymatic treatment thus avoiding a cell-bead separation step. 349 
However, gelatin beads with macro-size pores are not transparent, which makes it difficult to 350 
observe and judge the state of cells on the microcarriers during cell culture. With our 351 
differentiation protocol, hESCs attached and differentiated into hepatic cells on the different 352 
types of microcarriers. Microcarriers were coated with Matrigel to mask the collagen layer and 353 
thus promote initial hESC adhesion to the beads. Recombinant vitronectin protein coating is also 354 
commercially available and can carry hepatic differentiation of hESC when applied to 355 
microcarriers (Supplementary data Figure. 4.). This, even if vitronectin allows relatively low 356 
initial cell attachment compared to Matrigel, as it is a more defined ECM material, future studies 357 
should still investigate whether it is suitable for hESC microcarrier culture and hepatic 358 
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differentiation.  Among the 4 different microcarriers, dextran beads with collagen layer 359 
supported differentiation better than other types of microcarriers, and cells could easily be judged 360 
in culture due to the transparency of the beads. As all the beads were initially coated with 361 
Matrigel masking the biological effect of the underlying microcarrier material, we cannot 362 
address whether or how the collagen layer helped the hepatic differentiation from PSCs.  363 
The dextran microcarriers used in this study were microporous, with a void fraction exceeding 364 
90%. As the multi-step differentiation protocol introduces the cocktails of different growth 365 
factors to the differentiating cells to drive the differentiation to designed next step, it is likely that 366 
a significant amount of medium and growth factors used during the preceding step remains 367 
inside the cell-laden microcarriers during the following step. Growth factor gradients can be 368 
formed at the near surface of microcarriers. Although we did not see a significant difference 369 
between differentiation on tissue culture plates and on microcarriers, it remains to be determined 370 
whether cytokines remaining from the previous step of differentiation may have antagonistic or 371 
positive effects on the level of differentiation, definitely when bead concentration is increased 372 
further to near industrial level. In such a differentiation bioprocess, with a higher microcarrier 373 
concentration, the effect may not be negligible anymore. 374 
hESCs are typically passaged as colonies as hESCs do not survive well and maintain potency as 375 
single cells.  However, for microcarrier culture systems, colony inoculation impedes the precise 376 
control of cell number and the even distribution of cells on the beads, which is an obstacle for 377 
developing into a bioprocess. Initial studies were done using tissue culture plates, wherein we 378 
compared seeding and expanding cells using single cell suspensions without ROCK inhibitor for 379 
a short period with seeding colonies. The differentiation outcome was comparable in both 380 
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systems (Fig. 1). This seeding system was then adopted to microcarrier culture and showed 381 
successful attachment and even distribution of cells on the microcarriers (Fig. 3A).  382 
The microcarrier concentration used in this study was relatively low, and the culture was 383 
initiated with a relatively low inoculum of cells. The initial concentration was limited to 1 x 106 384 
cells/ml, a concentration that mimics conventional 2D differentiation in tissue culture plates. We 385 
inoculated cells onto microcarriers with a temporary reduced volume to increase the microcarrier 386 
and cell concentration, thereby increasing the probability of successful contacts between cells 387 
and microcarriers during the initial 2 hours of cell attachment period. High cell and microcarrier 388 
concentration and intermittent stirring aided initial cell distribution on microcarriers and 389 
consequently affected growth kinetics during expansion of hESCs as it was determined from the 390 
cell concentration after 3 days of culture (Supplementary data Table. 1.). hESC seeded on 391 
microcarriers proliferated with similar doubling times as in tissue culture plates. hESC did not 392 
form multiple layers on microcarriers, but cell-laden beads agglomerated both in static and 393 
spinner suspension culture systems. As cells do not form multilayers on microcarriers, cell 394 
density was limited to the surface area of the total number of microcarriers. Cells expanded by 3-395 
4 times during 2 day culture (Fig. 3). When the density reached the maximum, viable cells 396 
saturated on microcarriers, and the cell density did not increase further but was maintained. The 397 
high cell density during the initial 2 days of expansion did not affect the pluripotency markers 398 
expression of hESC. 399 
Following 2 days of expansion, cells were induced to hepatocyte-like cells using a standard 400 
differentiation protocol in the lab (Roelandt et al., 2012). With the initial cell concentration of 401 
1.0 x 106 cells/ml, differentiation in suspension culture system yielded the cell concentration of 5 402 
x 105 cells/ml at the end of differentiation, which was similar to cell concentrations found in 403 
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tissue culture plates (Fig. 4). We also tested in an initial experiment whether it would be feasible 404 
to increase the initial cell and bead concentration and still achieve efficient differentiation, by 405 
increasing the initial cell concentration to 4.0 x 106 cells/ml. This yielded the final concentration 406 
of progeny at 2.52 x 106 cells/ml at the end of differentiation with comparable hepatic gene 407 
expression and albumin secretion rate (Supplementary data Fig. 1). This thus suggests the 408 
potential of larger scale differentiation in more developed and sophisticated bioprocess.  409 
The extent of differentiation into hepatocyte-like cells on microcarriers was similar to that seen 410 
in 2D differentiation in culture dishes, as shown by qRT-PCR as well as functional assays (Fig. 4 411 
and 5, Table 2), even if functional characteristics still remained inferior to primary hepatocytes 412 
but similar to published studies on pluripotent stem cells (Hannan et al., 2013; Yusa et al., 2011). 413 
Albumin and urea rates from the differentiated ESCs are lower than that from primary 414 
hepatocytes (Roelandt et al., 2010). CYP3A4 specific activity is also about 5 times lower than 415 
that in hepatoma cell lines (Data not shown).  Only a few cells were positive for CYP3A4 and 416 
PEPCK in immunofluorescent staining (Fig. 5), in line with the qRT-PCR data, pointing to the 417 
fact that majority of cells differentiated in 2D, regardless of in culture dishes or on microbeads, 418 
do not reach a fully mature hepatocyte-like phenotype.  419 
We also demonstrated that microcarrier differentiation is possible in a spinner culture system, 420 
yielding hepatic cells with the similar levels of hepatocyte gene expression and function (Fig. 6). 421 
The final cell concentration in the spinner differentiation was similar to that in the static culture. 422 
Cell-laden microcarriers still agglomerated together in the presence of agitation at 20-25 rpm. As 423 
shear stress cannot be avoided in stirred bioreactor cultures, the effect of shear stress on the bead 424 
surface should be examined on stem cell differentiation. Shear stress can play as a critical 425 
parameter in designing successful hepatic differentiation in a stirred bioreactor. Stirring rates 426 
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above 30 rpm did not produce a stabilized environment for hESCs on microcarriers. hESC did 427 
not remain attached to the microcarriers during the initial phase of the expansion culture. hESC 428 
induced to differentiate to hepatocyte-like cells in tissue culture plates, down-regulated their 429 
integrin (cell surface receptor that mediates cell-ECM or cell-cell interaction) expression during 430 
the first half of the differentiation culture (Supplementary Fig. 3), which is a finding that will 431 
need to be assessed further especially as it relates to the presence of shear stress produced by 432 
stirring. At physiological levels, blood flow induces shear force in the hepatic sinusoid at 20-40 433 
dyn cm-2 which increases the functionality of hepatocytes (Kan et al., 2004). Recent studies have 434 
also shown that shear stress exerted on hESC-laden microcarriers induces differentiation of 435 
hPSC (Hw et al., 2011), and affects transcriptional regulation and promotion of endothelial-like 436 
cells during differentiation (Ahsan and Nerem, 2010; Mammoto et al., 2012). One method to 437 
decrease shear stress is combining microencapsulation with alginate and microcarrier culture 438 
(Serra et al., 2011).  439 
As we did not use encapsulation, it was necessary to decrease the stirring rate below 30 rpm. 440 
This reduced stirring rate caused some agglomeration of beads forming multilayers between the 441 
beads to form semi-3D structures. Theoretically, this semi-3D structure should enhance 442 differentiation (Nahmias et al., 2006). However, agglomeration creates a non-homogeneous 443 
differentiation environment due to various sizes of the clusters and diffusion limitation in the 444 
larger clusters. In 3D aggregation differentiation, aggregate size affects differentiated cell 445 types (Nieden et al., 2010; Ungrin et al., 2012; Van Hoof et al., 2011), and controlling cluster 446 size increased the efficiency of differentiating hESCs into endoderm cells (Bauwens et al., 447 2008; Peerani et al., 2009; Van Hoof et al., 2011).  448 
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Our study combines the proliferative characteristic of undifferentiated hESC and the high 449 
surface-to-volume ratio of microcarriers to induce larger-scale hepatic differentiation culture. 450 
This still translates the same problem that tissue culture plate differentiation of hESC faces to 451 
microcarrier culture; small population of functional hepatocytes is differentiated at the end of 452 
differentiation process. Shifting expansion phase from undifferentiated hESC to the immature 453 
hepatic cells may also amplify the efficacy of using microcarriers.  In vivo, hepatic oval cells 454 
form the proliferative phase as transit compartment precursor cells and differentiate into several 455 
types of cells including hepatocytes and biliary cells (Fausto and Campbell, 2003). In embryonic 456 
development, bipotent hepatoblasts are similar to in vivo hepatic oval cells by giving rise to both 457 
hepatocytes and biliary epithelial cells. These cells express both hepatocyte (AFP, albumin) and 458 
cholangiocyte (CK7, CK19, OV-6) markers (Behbahan et al., 2011). During hESC-hepatocyte 459 
differentiation, there is a proliferative phase from day 8 to day 12 of differentiation, and some 460 
cells express AFP and CK19 (Data not shown). Selecting proliferative hepatic precursor cells 461 
during the hepatic differentiation of hESC and expanding these cells on microcarriers may be 462 
able to increase the efficiency of harvesting mature hepatocytes at the end in a larger scale. 463 
However, more studies should be preceded if hepatoblasts themselves can alone be differentiated 464 
into fully functional hepatocytes without the help of surrounding other cell lineages. In addition, 465 
technically, hepatoblasts should tolerate dissociation, selection process and then seeding on to 466 
microcarriers. As much cell loss is expected after using enzymatic treatment and fastidious 467 
seeding procedure, surface property of both the cell and the bead should be carefully considered. 468 
We conclude that microcarrier suspension culture is feasible for hESC differentiation to the 469 
hepatic cell lineage. With more careful optimization, it will facilitate the transformation of the 470 
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laboratory practice of hESC culture to scalable bioprocess generating hepatocyte-like cells at 471 
industrial scales for future clinical applications. 472 
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